Get started
Author

Elisabeth Buur Stougaard

Observed names: Elisabeth B Stougaard, Elisabeth B. Stougaard, Elisabeth Buur Stougaard, Stougaard, Elisabeth B.
ORCID: 0000-0003-3463-1102
Observed ORCID: 0000-0003-3463-1102
OpenAlex ID: A5085506951
Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
2022 · Ninna H. Tougaard, Marie Frimodt-Møller, et al. · Journal of Clinical Medicine · 36
PDF
Diabetes Management During Breastfeeding in Women with Type 1 Diabetes
2020 · Lene Ringholm, Elisabeth Buur Stougaard, et al. · Current Diabetes Reports · 27
Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
2023 · Elisabeth B. Stougaard, Peter Rossing, et al. · Diabetes Obesity and Metabolism · 23
Sodium–glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines
2022 · Elisabeth B. Stougaard, Peter Rossing, et al. · Journal of Diabetes and its Complications · 15
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis
2022 · Elisabeth B Stougaard, Peter L Kristensen, et al. · Diabetes and Vascular Disease Research · 14
The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes—rationale and protocol of the prospective, randomized, open‐labelled multicentre study
2025 · Elisabeth B. Stougaard, Mads R. Andersen, et al. · Diabetes Obesity and Metabolism · 13
PDF
Effects of probiotics and fibers on markers of nephropathy, inflammation, intestinal barrier dysfunction and endothelial dysfunction in individuals with type 1 diabetes and albuminuria. The ProFOS Study
2024 · Elisabeth B. Stougaard, Ninna Hahn Tougaard, et al. · Journal of Diabetes and its Complications · 12
PDF
Lower Blood Oxygen Saturation is Associated With Microvascular Complications in Individuals With Type 1 Diabetes
2022 · Jens Christian Laursen, Hatice Isik Mizrak, et al. · The Journal of Clinical Endocrinology & Metabolism · 11
Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2
2025 · Massimo Nardone, Luxcia Kugathasan, et al. · Clinical Journal of the American Society of Nephrology · 10
Time Trends in the Incidence of Diabetic Ketoacidosis Leading to Hospital Admission Among Adults With Type 1 Diabetes: A Nationwide Danish Register Study
2023 · Elisabeth B. Stougaard, Hanan Amadid, et al. · Diabetes Care · 10
Combining SGLT2is, GLP1-RAs and nsMRAs in Diabetes: A Scoping Review of Current and Future Perspectives
2025 · Elisabeth Buur Stougaard, Viktor Rotbain Curovic, et al. · Diabetes Therapy · 8
Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes
2021 · Elisabeth Buur Stougaard, Signe Abitz Winther, et al. · PLoS ONE · 8
PDF
Modeling Cardiovascular Protection With SGLT Inhibition in Type 1 Diabetes: A Risk-Based Approach to Guide Therapy?
2025 · Luxcia Kugathasan, Pritha Dutta, et al. · Diabetes Care · 5
Slowing the progression of diabetic and non‐diabetic kidney disease: A summary of the current evidence base for sodium‐glucose co‐transporter‐2 inhibitors
2024 · Viktor Rotbain Curovic, Elisabeth Buur Stougaard, et al. · Diabetes Obesity and Metabolism · 4
PDF
GLP-1 receptor agonists in patients with type 2 diabetes: cardiorenal protection versus ocular safety
2026 · Elisabeth Buur Stougaard, Peter Rossing · Nephrology Dialysis Transplantation
Evaluating Cardiovascular Benefit of Sotagliflozin Across Kidney and Cardiovascular Risk in Type 1 Diabetes: Modeling Analysis of the inTandem1–3 Trials
2026 · Luxcia Kugathasan, Vikas S. Sridhar, et al. · Diabetes Obesity and Cardiometabolic CARE
PDF
Author response for "Slowing the progression of diabetic and non‐diabetic kidney disease: A summary of the current evidence base for sodium‐glucose co‐transporter‐2 inhibitors"
2024 · Viktor Rotbain Curovic, Elisabeth Buur Stougaard, et al. · Publons reviews and discussion
Effects of Probiotics and Fibers on Markers of Nephropathy and Endothelial Dysfunction in Persons with Type 1 Diabetes and Albuminuria
2023 · Elisabeth B. Stougaard, Ninna H. Tougaard, et al. · Journal of the American Society of Nephrology
Author response for "Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and kidney disease as assessed by Steno T1 Risk Engine in adults with type 1 diabetes"
2023 · Elisabeth B Stougaard, Peter Rossing, et al. · Publons reviews and discussion
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, Reduces the Risk of Cardiovascular and Renal Disease as Assessed by Steno Risk Engines in Adults With Type 1 Diabetes
2022 · Elisabeth B. Stougaard, Peter Rossing, et al. · Journal of the American Society of Nephrology
396-P: Real-Life Evaluation of Sodium–Glucose Cotransporter 2 Inhibition in Type 1 Diabetes
2022 · ELISABETH BUUR STOUGAARD, PETER L. KRISTENSEN, et al. · Diabetes
406-P: Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Trial
2022 · NINNA H. TOUGAARD, MARIE FRIMODT-MOELLER, et al. · Diabetes
Sodium-Glucose Cotransporter 2 Inhibitors as Adjunct Therapy for Type 1 Diabetes and the Benefit on Cardiovascular and Renal Disease Evaluated by Steno Risk Engines
2021 · Elisabeth B. Stougaard, Dorte Vistisen, et al. · Journal of the American Society of Nephrology
380-P: Endothelial Glycocalyx Dimensions and Cardiovascular Risk Factors in Type 1 Diabetes
2021 · ELISABETH BUUR STOUGAARD, SIGNE WINTHER, et al. · Diabetes
[SGLT 2 inhibitors in Type 1 diabetes].
2020 · Elisabeth Buur Stougaard, Hanan Amadid, et al. · PubMed
Works count: 26
Citation count: 196
H-index: 10
I10-index: 10
Year
Topic
Type